Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders

Psychopharmacology

Volumn 179, Issue 3, 2005, Pages 629-636

  Gagiano, Carllo ^a   Read, Stephen ^b   Thorpe, Lilian ^c   Eerdekens, Mariëlle ^d   Van Hove, Ilse ^d  

^a Westdene Research Center   (South Africa)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Disruptive behavior disorder; Intellectually disabled; Risperidone

Indexed keywords

PLACEBO; PROLACTIN; RISPERIDONE;

ABDOMINAL PAIN; ADULT; AGGRESSION; AMENORRHEA; APATHY; ARTICLE; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FATIGUE; FEMALE; GAIT DISORDER; GALACTORRHEA; GLUCOSE METABOLISM; HEADACHE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; INJURY; INSOMNIA; INTELLECTUAL IMPAIRMENT; INTERMITTENT EXPLOSIVE DISORDER; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; OPPOSITIONAL DEFIANT DISORDER; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; PSYCHOPATHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; RHINITIS; SOMNOLENCE; TREMOR; VOMITING;

ADOLESCENT; ADULT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE;

EID: 18744362168     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2093-2     Document Type: Article

References (31)

1. Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22-31
2. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491
3. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the Risperidone Disruptive Behavior Study Group (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
4. Brar JS, Ganguli, R, Pandina, G, Turkoz I, Berry S, Mahmoud R (in press) Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry
5. Buitelaar JK (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnosis and aggressive behavior. J Child Adolesc Psychopharmacol 10:19-26
6. Chouinard G, Ross-Canard A, Annable L, Jones BD (1980) The extrapyramidal symptom rating scale [abstract]. Can J Neurol Sci 7:233
7. Cohen SA, Ihrig K, Lott RS, Kerrick JM (1998) Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 28:229-233
8. Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22
9. Dartnall NA, Holmes JP, Morgan SN, McDougle CJ (1999) Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 29:87-91
10. Emerson E, Kiernan C, Alborz A, Reeves D, Mason H, Swarbrick R, Mason L, Hatton C (2001) The prevalence of challenging behaviors: a total population study. Res Dev Disabil 22:77-93
11. Farrington DP, Gallagher B, Morley L, St Ledger RJ, West DJ (1988) Are there any successful men from criminogenic backgrounds? Psychiatry 51:116-130
12. Fergussen DM, Horwood LJ (1998) Early conduct problems and later life opportunities. J Child Psychol Psychiatry 39:1097-1108
13. Findling RL, Maxwell K, Wiznitzer M (1997) An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33:155-159
14. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psych 39:509-516
15. Guy W (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology, revised 1976. National Institute of Mental Health, Rockville, MD, pp 217-222
16. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH (1995) Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5: 273-282
17. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psych 36:683-693
18. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psych 37:372-376
19. Purdon SE, Lit W, Labelle A, Jones BD (1994) Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400-405
20. Robins LN (1966) Deviant children grow up: a sociological and psychiatric study of sociopathic personality. Williams & Wilkins, Baltimore, MD
21. Rojahn J (1992) Behavior problems inventory: a prospectus. Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University
22. Santosh PJ, Baird G (1999) Psychopharmacotherapy in children and adults with intellectual disability. Lancet 354:233-242
23. Simon EW, Blubaugh KM, Pippidis M (1996) Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Ment Retard 34:359-366
24. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, and the Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psych 41: 1026-1036
25. Swann AC (2003) Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 64(Suppl 4):26-35
26. Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110: e34
27. Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13
28. Van Elteren PH (1960) On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 37:351-361
29. Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutjens J, Sieben G, Heylen S (1993). Risperidone as add-on therapy in behavioral disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167-171
30. Werneke U, Taylor D, Sanders TAB (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 17:145-160
31. Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, Fleming K, Shores R, Williams D, Schroeder SR (2001) Effects of risperidone on aberrant behavior of persons with developmental disabilities: a double-blind crossover study using multiple measures. Am J Ment Retard 106:525-538